Source: [europepmc](https://pubmed.ncbi.nlm.nih.gov/42177520/)
Authors: Khademi M, Kazemifard N, Fathi M, Farmani M, Baradaran Ghavami S, Khanabadi B, Shahrokh S.
Venue: BMC complementary medicine and therapies · 2026-05-23
Abstract
<h4>Background</h4>Disruption of the intestinal epithelial barrier is a hallmark of inflammatory bowel disease (IBD). Although probiotics and postbiotics are increasingly recognized as potential therapeutic approaches, treatment efficacy is often influenced by patient-specific variability.<h4>Methods</h4>In this study, intestinal inflammation was modeled by exposing HT-29 cells to fecal supernatants (FS) derived from three patients with ulcerative colitis (UC). The expression of pro-inflammatory (IL-8) and barrier-associated (Claudin-1, MUC2) genes was assessed by real-time PCR. Subsequently, the restorative effects of different preparations of Lactobacillus helveticus SBT2171, including live bacteria, cell-free supernatant, and debris-containing supernatant, were evaluated at 24 and 48 h.<h4>Results</h4>FS exposure significantly upregulated IL-8 expression while downregulating Claudin-1 and MUC2, thereby recapitulating IBD-associated epithelial disruption. Treatment with L. helveticus preparations partially restored barrier-related gene expression in a patient- and treatment-dependent manner. Live bacteria induced transient or sustained Claudin-1 upregulation depending on the FS source, whereas the cell-free supernatant demonstrated broader and more durable restorative effects across distinct inflammatory contexts. In contrast, debris-containing preparations exerted limited or even suppressive effects, particularly on MUC2 expression.<h4>Conclusions</h4>These findings demonstrate that the barrier-restorative effects of L. helveticus in vitro is not uniform but shaped by the unique inflammatory and microbial environment of each patient. Collectively, our results support the potential of postbiotic formulations as safer and effective modulators of epithelial barrier repair and underscore the need for personalized strategies in microbiota-based therapies for IBD.
AI relevance (5/5): Directly addresses intestinal barrier recovery via MUC2 and Claudin-1 expression in UC-derived inflammation model.
--- *Draft auto-created from Suggestions queue. Polish the body, set is_real=true when verified, and publish via `INSERT INTO bionoia_published` when ready for /public/.*